Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
2(17%)
Results Posted
86%(6 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_1
6
50%
Ph phase_2
5
42%

Phase Distribution

6

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
6(54.5%)
Phase 2Efficacy & side effects
5(45.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(7)
Terminated(2)
Other(1)

Detailed Status

Completed7
Terminated2
unknown1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
77.8%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (54.5%)
Phase 25 (45.5%)

Trials by Status

unknown18%
completed758%
active_not_recruiting18%
recruiting18%
terminated217%

Recent Activity

2 active trials
Showing 5 of 12
active_not_recruitingphase_1

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

NCT02057133
unknown

Master Rollover Protocol for Continued Safety Assessment of Study Drug

NCT02632994
terminatedphase_1

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

NCT02784795
recruitingphase_2

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

NCT03675893
completedphase_2

Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

NCT02549989
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT02057133Phase 1

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Active Not Recruiting
NCT02632994

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Unknown
NCT02784795Phase 1

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Terminated
NCT03675893Phase 2

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Recruiting
NCT02549989Phase 2

Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

Completed
NCT01655225Phase 1

A Study of LY3023414 in Participants With Advanced Cancer

Completed
NCT02407054Phase 2

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

Completed
NCT02443337Phase 2

A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

Terminated
NCT02079636Phase 1

A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

Completed
NCT02124148Phase 1

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

Completed
NCT02981342Phase 2

A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma

Completed
NCT02536586Phase 1

A Study of LY3023414 in Japanese Participants With Advanced Cancer

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12